高级别星形细胞瘤病程中新出现的不可测量斑点状对比增强病灶与IDH突变相关
该研究回顾性分析746例胶质瘤患者的MRI,评估病程中新出现的不可测量斑点状对比增强病灶(SCEs)与分子及临床基线参数的关系及预后影响。SCEs在WHO 2级和3级星形细胞瘤及少突胶质细胞肿瘤中更常见,在WHO 3级星形细胞瘤和胶质母细胞瘤中与异柠檬酸脱氢酶(IDH)突变显著相关。SCEs多保持稳定或消退,在胶质母细胞瘤中与良好预后相关,作者强调应谨慎定义进展并定期随访而非过早启动新抗肿瘤治疗。
要点
- SCEs在WHO 2级和3级星形细胞瘤及少突胶质细胞肿瘤中更常见。
- 在WHO 3级星形细胞瘤和胶质母细胞瘤中,SCEs与IDH突变显著相关。
- 胶质母细胞瘤中SCEs与良好预后相关,包括IDH野生型亚组。
核心结论
- SCEs出现后多呈良性病程,应谨慎定义进展并定期临床和影像随访,而非在确认进展前过早启动新抗肿瘤治疗。
研究设计与样本
- 回顾性修订746例胶质瘤患者的磁共振成像,评估病程中新检测到的SCEs,并统计分析其与分子和临床基线参数的关系及预后影响。
主要发现
- SCEs在WHO 2级和3级星形细胞瘤及少突胶质细胞肿瘤中更常见。
- 在WHO 3级星形细胞瘤和胶质母细胞瘤中,SCEs与IDH突变显著相关。
- SCEs在随访磁共振成像中多保持稳定或消退,即使未启动新治疗。
- SCEs常位于肿瘤内或肿瘤相关FLAIR异常区域内,但也可出现在远处。
- 在胶质母细胞瘤患者中,SCEs与良好预后相关,在IDH野生型胶质母细胞瘤亚组中亦观察到该关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Because treatment options at progression are limited for patients with glioma, accuracy in definition of progression is pivotal. Clinically asymptomatic, newly detected, nonmeasurable, speckled contrast-enhancing lesions (SCEs) without immediate relation to prior immune therapy or radiation therapy appear relatively frequently during the course of disease in patients with glioma and challenge the definition of progression based on Response Assessment in Neuro-oncology criteria. Therefore, data characterizing these SCEs are needed for recommendations of subsequent clinical management. MATERIALS AND METHODS: Magnetic resonance imaging of 746 patients with glioma included in this study were retrospectively revised for appearance of newly detected SCEs during the course of disease. Associations with molecular and clinical baseline parameters and their prognostic impact were statistically analyzed, and frequency, natural course, and location of SCEs were described. RESULTS: SCEs occurred more frequently in World Health Organization grade 2 and 3 astrocytoma and oligodendroglial tumors and were significantly associated with isocitrate dehydrogenase mutation in World Health Organization grade 3 astrocytoma and glioblastoma. SCEs mostly remained stable or dissolved in follow-up magnetic resonance imaging, even if no new treatment was initiated. SCEs were frequently located within the tumor or tumor-associated fluid-attenuated inversion recovery abnormalities, but distant appearance also occurred. In patients with glioblastoma, SCEs were associated with a favorable prognosis, which was also observed in the subgroup of patients with glioblastoma with isocitrate dehydrogenase wildtype status. CONCLUSIONS: The data demonstrate a predominantly benign course of SCEs after their appearance and emphasize cautious definitions of progression and regular clinical and radiographic follow-up rather than premature initiation of new antitumor therapies until progression is confirmed.
引用
- Berberich A, Hielscher T, Kickingereder P, et al. Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. Int J Radiat Oncol Biol Phys. 2018. PMID: 30071292. doi:10.1016/j.ijrobp.2018.07.2004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。